| Drug Name |
Lubiprostone |
| Drug ID |
BADD_D01328 |
| Description |
Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. Activation of these channels promotes the secretion of a chloride-rich fluid that soften the stool, increase gastrointestinal motility, and induce spontaneous bowel movements (SBM). |
| Indications and Usage |
For the treatment of chronic idiopathic constipation in the adult population. Also used for the treatment of irritable bowel syndrome with constipation in women who are 18 years of age or older. |
| Marketing Status |
Prescription |
| ATC Code |
A06AX03 |
| DrugBank ID |
DB01046
|
| KEGG ID |
D04790
|
| MeSH ID |
D000068238
|
| PubChem ID |
157920
|
| TTD Drug ID |
D00CTS
|
| NDC Product Code |
64764-240; 11014-0011; 0254-3028; 65162-842; 11014-0010; 64764-080; 71796-041; 68245-0011; 0254-3029; 65162-841; 76397-025; 55700-963; 76397-012; 65035-132; 54893-0093 |
| Synonyms |
Lubiprostone | Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)- | RU 0211 | 0211, RU | RU0211 | RU-0211 | Amitiza | SPI 0211 | 0211, SPI | SPI0211 | SPI-0211 |
